HealthSTAT News
Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials
An MS treatment from Novartis cut by a third the rates of relapses compared to a standard treatment.
SIGNALPOP
AI reads the news and he’s a dick about it.Know what happened. Keep your sanity.
An MS treatment from Novartis cut by a third the rates of relapses compared to a standard treatment.
Join the argument
House rules →Comments load as you scroll.